4LLY
Crystal structure of Pertuzumab Clambda Fab with variable and constant domain redesigns (VRD2 and CRD2) at 1.6A
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | APS BEAMLINE 31-ID |
Synchrotron site | APS |
Beamline | 31-ID |
Detector technology | CCD |
Collection date | 2013-02-11 |
Detector | RAYONIX MX225HE |
Wavelength(s) | .97931 |
Spacegroup name | P 1 |
Unit cell lengths | 52.772, 52.847, 89.483 |
Unit cell angles | 76.88, 84.32, 85.53 |
Refinement procedure
Resolution | 30.000 - 1.600 |
R-factor | 0.19931 |
Rwork | 0.198 |
R-free | 0.22929 |
Structure solution method | MOLECULAR REPLACEMENT |
RMSD bond length | 0.009 |
RMSD bond angle | 1.384 |
Data reduction software | MOSFLM |
Data scaling software | SCALA |
Phasing software | PHASER |
Refinement software | REFMAC (5.7.0017) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 43.420 | 1.690 |
High resolution limit [Å] | 1.600 | 1.600 |
Number of reflections | 118271 | |
Completeness [%] | 95.9 | 94.3 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, SITTING DROP | 5 | 294 | 100mM Na Citrate tribasic dihydrate pH 5 + 30% Jeffamine ED-2001 , VAPOR DIFFUSION, SITTING DROP, temperature 294K |